Image de couverture de livre

Real World Adverse Effects of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis Ages 6–11 Years

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Rebecca S. Pettit, Bharathi Ravikumar
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Pediatric Pulmonology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis
par: Cindy L. Williams, et autres
Publié: (2025)

Papilledema in Children With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Case Series
par: Charissa W. Kam, et autres
Publié: (2024)

Real‐World Impact of Elexacaftor/Tezacaftor/Ivacaftor in Israeli Children Aged 2–6 With Cystic Fibrosis
par: Adi Dagan, et autres
Publié: (2026)

Effects of Elexacaftor‐Tezacaftor‐Ivacaftor on Nasal and Sinus Symptoms in Children With Cystic Fibrosis
par: Guillaume Petit, et autres
Publié: (2025)

Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis
par: Sara Kümmerli, et autres
Publié: (2026)

Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis
par: Burcu Uzunoglu, et autres
Publié: (2025)

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase‐1 in Children With Cystic Fibrosis
par: Senthilkumar Sankararaman, et autres
Publié: (2025)

Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy
par: Kimberly Pasley, et autres
Publié: (2024)

Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation
par: Esben Herborg Henriksen, et autres
Publié: (2025)

A Tale of Two Infants: Off‐Label Use of Elexacaftor/Tezacaftor/Ivacaftor in Early Cystic Fibrosis Treatment
par: Nour K. Kadouh, et autres
Publié: (2025)

Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis
par: Emma R. Lyons, et autres
Publié: (2025)

The Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study
par: Sasha‐Jane Abi‐Aad, et autres
Publié: (2026)

Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross‐Sectional Single‐Centre Study
par: Lauren J. Clayton, et autres
Publié: (2025)

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis
par: Christos Kogias, et autres
Publié: (2026)

Improving Pancreatic Function With Elexacaftor/Tezacaftor/Ivacaftor
par: Madison Pranske, et autres
Publié: (2026)

Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States
par: Sonia Graziano, et autres
Publié: (2025)

Effects of an Exercise Intervention on Exercise Capacity in Adults With Cystic Fibrosis: A Quasi‐Experimental Study Comparing Individuals Treated With and Without Elexacaftor/Tezacaftor/Ivacaftor
par: Wolfgang Gruber, et autres
Publié: (2025)

Tobramycin Pharmacokinetics in Pediatric People With Cystic Fibrosis on Maintenance Azithromycin
par: Chelsea Flora, et autres
Publié: (2026)

Crushing Elexacaftor/Tezacaftor/Ivacaftor Oral Granules for Gastrostomy Tube Administration
par: Alexander S. Kim, et autres
Publié: (2025)

Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center
par: Lena Papadakis, et autres
Publié: (2024)

Lung T1‐MRI and Multi‐Breath Washout Detect Longitudinal Changes in Children 6–11 Years Old After Beginning Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy
par: Samya Z. Nasr, et autres
Publié: (2026)

Diabetes remission in adults with cystic fibrosis commenced on Elexacaftor/Tezacaftor/Ivacaftor: A single center case‐series
par: Shanal Kumar, et autres
Publié: (2024)

Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients
par: Jochen G. Mainz, et autres
Publié: (2026)

Variable Response to Elexacaftor/Tezacaftor/Ivacaftor in [L467F;F508del] Homozygous Patients: A Case Series
par: Meltem Akgül Erdal, et autres
Publié: (2026)

Impact of Number of Pharmacies on Dornase Alfa Medication Possession Ratio in Children With Cystic Fibrosis
par: Rebecca S. Pettit, et autres
Publié: (2025)

Elexacaftor/Tezacaftor/Ivacaftor Effect on a Patient With Rare Compound Heterozygous CFTR Splice Variant Genotype C.[1393‐1G>A;2988+1G>A]
par: Maria Moustaki, et autres
Publié: (2025)

Lung clearance index (LCI2.5) changes after initiation of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis aged between 6 and 11 years: The “real‐world” differs from trial data
par: Don S. Urquhart, et autres
Publié: (2024)

Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real‐Life Study
par: A. M. Zwitserloot, et autres
Publié: (2025)

Predictors of Selective Serotonin Reuptake Inhibitor Treatment Failure in Persons With Cystic Fibrosis
par: Rebecca S. Pettit, et autres
Publié: (2024)

Cystic Fibrosis Year in Review 2024
par: Adrienne P. Savant
Publié: (2025)

Infant Lung Function in Cystic Fibrosis: A Real‐World Study
par: Michele Arigliani, et autres
Publié: (2025)

Expanding Cystic Fibrosis Registries to the Rest of the World
par: Lutz Naehrlich
Publié: (2026)

Systematic Review of Nasal Endoscopy Scores in Cystic Fibrosis Patients Treated With Cystic Fibrosis Transmembrane Conductance Regulator Modulators
par: Rebecca Gallardo, et autres
Publié: (2026)

Associations Between Socioeconomic Status and Adherence to Medications in People With Cystic Fibrosis
par: Gabriela R. Oates, et autres
Publié: (2025)

Linaclotide Use for the Treatment of Constipation and Gastrointestinal Symptoms in People With Cystic Fibrosis
par: Lauren N. Kormelink, et autres
Publié: (2024)

C‐Reactive Protein Changes in Adult and Pediatric People With Cystic Fibrosis During Treatment of Pulmonary Exacerbations
par: Jonathan B. Zuckerman, et autres
Publié: (2025)

Feeding the Need: A Study on Food Security Among People With Cystic Fibrosis in Turkey
par: Damla Kocaman, et autres
Publié: (2025)

Facilitators and Barriers to Increasing Equity in Cystic Fibrosis Newborn Screening Algorithms
par: Kellyn Madden, et autres
Publié: (2024)

The Impact of Cystic Fibrosis‐Related Diabetes on Barriers to Self‐Management
par: Rebecca J. Vitale, et autres
Publié: (2026)

The Impact of Attention Deficit Hyperactivity Disorder on Home Spirometry and Other Parameters in People With Cystic Fibrosis
par: Aqeem Azam, et autres
Publié: (2025)